Monte Rosa Therapeutics, Inc. operates in the field of targeted protein degradation, leveraging its Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform to design selective molecular glue degraders (MGDs). These small molecule therapeutics are designed to utilize the body's natural protein degradation machinery to eliminate disease-driving proteins. The company's clinical pipeline includes MRT-2359, an orally bioavailable degrader targeting MYC-driven solid tumors, alongside other programs such as MRT-6160 for immune-mediated diseases and MRT-8102. Headquartered in Boston with additional operations in Basel, Switzerland, Monte Rosa collaborates with major pharmaceutical companies, including Novartis, to expand the application of its MGD technology across various therapeutic areas.
